BlackRock MuniHoldings California Quality Fund, Inc. (MUC)
Stock analysis · NYSE · Financial Services · Asset Management
BlackRock MuniHoldings California Quality Fund, Inc. (MUC) is a publicly traded company in the Financial Services sector. Latest price: $10.01. Market cap $1.25B. Trailing PE 10.36. Dividend yield 6.41%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Proprietary Signals
About BlackRock MuniHoldings California Quality Fund, Inc.
The BlackRock MuniHoldings California Quality Fund, Inc. (MUC) is a closed-end investment vehicle initially brought to market by BlackRock, Inc. Its day-to-day management falls under the purview of BlackRock Advisors, LLC. This fund primarily allocates capital within the fixed-income sector, focusing predominantly on a portfolio of high-quality, long-term municipal debt instruments. A significant benefit of these holdings is that the interest they generate is exempt from both federal and California state income taxes. MUC was established in 1997 and operates from its domicile in the United States.
Valuation
| P/E (TTM) | 10.36× |
|---|---|
| P/S (TTM) | 12.42× |
| P/B | 0.87× |
| PEG | 0.01× |
| P/FCF (TTM) | 22.18× |
| EV / EBITDA | 19.56× |
| EV / Sales | 22.19× |
| Earnings Yield | 7.30% |
| Free Cash Flow Yield | 4.51% |
| Dividend Yield | 6.41% |
Fundamentals
| Enterprise Value | $2.24B |
|---|---|
| Revenue (TTM) | $100.79M |
| Net Income (TTM) | $91.30M |
| Free Cash Flow (TTM) | $79.50M |
| Net Debt | $985.70M |
| Working Capital | $98.93M |
| Gross Margin | 83.55% |
| Operating Margin | 113.49% |
| Net Margin | 90.58% |
| Return on Equity | 7.17% |
| Return on Invested Capital | 4.65% |
Peers
Recent News
- ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
- Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (L…
- Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Related
Browse more tickers: sitemap